ADPTのニュース
Morgan Stanley maintains Adaptive Biotechnologies at Equalweight with a price target of $14.00 2023/05/06 02:33:37 Investing.com
https://www.investing.com/news/pro/adaptive-biotechnologies-corp-receives-investment-bank-analyst-rating-update-3074998
Adaptive Biotechnologies Corporation (ADPT) Q1 2023 Earnings Call Transcript 2023/05/04 03:16:09 Seeking Alpha
Adaptive Biotechnologies Corporation (NASDAQ:NASDAQ:ADPT) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ETCompany ParticipantsKarina Calzadilla - Vice President of Investor…
Adaptive Biotechnologies GAAP EPS of $0.40 beats by $0.78, revenue of $37.6M beats by $0.69M 2023/05/03 21:12:20 Seeking Alpha
Adaptive Biotechnologies press release (ADPT): Q1 GAAP EPS of $0.40 beats by $0.78.Revenue of $37.6M (-2.6% Y/Y) beats by $0.69M.2023 Financial GuidanceAdaptive…
Adaptive Biotechnologies: Q1 Earnings Insights 2023/05/03 20:50:33 Benzinga
Adaptive Biotechnologies (NASDAQ: ADPT ) reported its Q1 earnings results on Wednesday, May 3, 2023 at 04:05 PM. Here''s what investors need to know about the announcement. Earnings Adaptive Biotechnologies missed estimated earnings by 5.26%, reporting an EPS of $-0.4 versus an … Full story available on Benzinga.com
Adaptive Biotechnologies: Q1 Earnings Snapshot 2023/05/03 20:15:26 WTOP
SEATTLE (AP) — SEATTLE (AP) — Adaptive Biotechnologies Corp. (ADPT) on Wednesday reported a loss of $57.7 million in its…
Adaptive Biotechnologies Corporation (ADPT) Q1 2023 Earnings Call Transcript 2023/05/04 03:16:09 Seeking Alpha
Adaptive Biotechnologies Corporation (NASDAQ:NASDAQ:ADPT) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ETCompany ParticipantsKarina Calzadilla - Vice President of Investor…
Adaptive Biotechnologies GAAP EPS of $0.40 beats by $0.78, revenue of $37.6M beats by $0.69M 2023/05/03 21:12:20 Seeking Alpha
Adaptive Biotechnologies press release (ADPT): Q1 GAAP EPS of $0.40 beats by $0.78.Revenue of $37.6M (-2.6% Y/Y) beats by $0.69M.2023 Financial GuidanceAdaptive…
Adaptive Biotechnologies: Q1 Earnings Insights 2023/05/03 20:50:33 Benzinga
Adaptive Biotechnologies (NASDAQ: ADPT ) reported its Q1 earnings results on Wednesday, May 3, 2023 at 04:05 PM. Here''s what investors need to know about the announcement. Earnings Adaptive Biotechnologies missed estimated earnings by 5.26%, reporting an EPS of $-0.4 versus an … Full story available on Benzinga.com
Adaptive Biotechnologies: Q1 Earnings Snapshot 2023/05/03 20:15:26 WTOP
SEATTLE (AP) — SEATTLE (AP) — Adaptive Biotechnologies Corp. (ADPT) on Wednesday reported a loss of $57.7 million in its…
Adaptive Biotechnologies Reports First Quarter 2023 Financial Results 2023/05/03 20:05:00 GlobeNewswire
SEATTLE, May 03, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2023.
Adaptive Biotechnologies stock pops on Takeda pact for use of clonoSEQ test 2023/04/12 12:29:52 Seeking Alpha
Adaptive Biotechnologies (ADPT) is collaborating with Takeda (TAK) to use its clonoSEQ test to detect minimal residual disease for Takeda''s drugs. Read more here
Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline 2023/04/12 11:30:00 GlobeNewswire
Collaboration will cover existing and future programs to aid in the development and commercialization of investigational medicines for hematologic malignancies Collaboration will cover existing and future programs to aid in the development and commercialization of investigational medicines for hematologic malignancies
Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ Assay Across Its Hematologic Malignancy Pipeline 2023/04/12 11:30:00 Wallstreet:Online
Collaboration will cover existing and future programs to aid in the development and commercialization of investigational medicines for hematologic malignancies SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose
Adaptive Biotechnologies stock falls ~10% amid COO termination 2023/04/11 17:30:59 Seeking Alpha
Adaptive Biotechnologies (ADPT) stock fell after the company said it is terminating the services of its Chief Operating Officer Mark Adams by May. Read more here
Adaptive Biotechnologies to Report First Quarter Financial Results on May 3, 2023 2023/04/06 20:05:00 GlobeNewswire
SEATTLE, April 06, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2023 after market close on Wednesday, May 3, 2023. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.